

ESPI Current Report No.21/2025

Date of preparation: 2025-03-26

Subject: Update of information on the implementation of Genomtec's strategic development directions – Establishment of special purpose vehicles as part of the change in the Company's organizational structure related to adaptation to the requirements of the M&A process.

Legal basis: Art. 17 sec. 1 MAR - confidential information.

Report content:

With reference to Current Report No. 29/2024 regarding changes in the organizational structure of the Company related to adaptation to the requirements of the M&A process and the strategic directions of development of Genomtec, the Management Board of Genomtec S.A. (the "Company", "Issuer", "Genomtec") informs that on March 26, 2025, two special purpose vehicles were established: GMT ID S.A. and GMT Genomics S.A., in which the Issuer became the 100% shareholder.

In accordance with the information provided in the aforementioned current report to the special purpose vehicles GMT ID and GMT Genomics in the form of The organized part of the enterprise will receive tangible and intangible assets related to the Genomtec ID project and the Onco-SNAAT product area, respectively.

The establishment of the above-mentioned special purpose vehicles was preceded by obtaining a preliminary decision of PARP and obtaining a positive tax interpretation, which states that the contribution of tangible and intangible assets related to the ID product area and the Onco-SNAAT product area as a capital contribution to the special purpose vehicles will be tax neutral for the Company. As of the date of publication of this current report, the Company is awaiting the decision of NCBR. The consequence of the above actions will be convening the General Meeting of the Company.

The Company will inform about subsequent important stages related to the implementation of the strategic directions of development of Genomtec in appropriate reports.